Treatment of malignant hypercalcaemia with clodronate
- PMID: 3158326
- PMCID: PMC1977044
- DOI: 10.1038/bjc.1985.100
Treatment of malignant hypercalcaemia with clodronate
Abstract
We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
